OBJECTIVE: Studies in mice have suggested that endocannabinoid blockade using the cannabinoid receptor type 1 (CB 1 ) blocker rimonabant prevents obesity-induced hepatic steatosis. DESIGN AND SUBJECTS: To determine effects of rimonabant on liver fat in humans, we measured liver fat content by proton magnetic resonance spectroscopy in 37 subjects who used either a CB 1 blocker rimonabant or placebo in a double-blind, randomized manner. This was retrospectively compared with a historical hypocaloric diet weight loss group (n ¼ 23). RESULTS: Weight loss averaged 8.5±1.4 kg in the rimonabant, 1.7±1.0 kg in the placebo and 7.5±0.2 kg in the hypocaloric diet group (Po0.001, rimonabant vs placebo; NS, rimonabant vs hypocaloric diet). Liver fat decreased more in the rimonabant (5.9% (2.5-14.6%) vs 1.8% (0.9-3.5%), before vs after) than in the placebo group (6.8% (2.2-15.7%) vs 4.9% (1.6-7.8%), before vs after, Po0.05). The percentage change in body weight correlated closely with the percentage loss of liver fat (r ¼ 0.70, P40.0001). The decreases in liver fat were comparable between the rimonabant and the young historical hypocaloric diet groups. CONCLUSIONS: We conclude that, unlike in mice, in humans rimonabant decreases liver fat in proportion to weight loss.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver disorder, and the only chronic liver disease whose prevalence is steadily increasing. 1 It covers a range of abnormalities from simple steatosis to non-alcoholic steatohepatitis. 2 NAFLD can be regarded as the hepatic manifestation of the metabolic syndrome, as the liver, once fatty, is insulin resistant and overproduces both glucose and triglycerides. 3 This leads to hyperglycemia and hyperinsulinemia as well as to hypertriglyceridemia and a low high-density lipoprotein cholesterol concentration. 4 NAFLD predicts type 2 diabetes, cardiovascular disease and advanced liver disease. 4 Reduction of liver fat seems, therefore, an attractive drug target.
Endocannabinoids such as anandamide and 2-arachidonoylglycerol are endogenous lipid agonists of the cannabinoid receptor type 1 (CB 1 ). CB 1 is expressed in the brain and in peripheral organs, such as the autonomic nervous system, liver, muscle, gastrointestinal tract and adipose tissue. 5 CB 1 knockout mice exposed to diet-induced obesity do not develop insulin resistance, dyslipidemia or a fatty liver. 6, 7 Liver-specific CB 1 knockout mice fed a high-fat diet develop a similar degree of obesity as wild-type mice on the same chow, but have less hepatic steatosis, hyperglycemia, dyslipidemia and insulin resistance than their wild-type littermates. 7 These animal data suggest that CB 1 blockade prevents obesity-induced hepatic steatosis and the accompanying metabolic changes.
Effects of rimonabant on liver fat in humans have not been quantitated. This study was undertaken to determine how changes in body weight induced by a CB 1 blockade as compared with placebo in humans influences liver fat content measured by proton magnetic resonance spectroscopy ( 1 H-MRS). As CB 1 blockade results in greater weight loss than placebo, [8] [9] [10] [11] we also wished to compare the present data to a young historical hypocaloric diet group, which had been previously studied in our laboratory 12 and lost an equal amount of body weight as the rimonabant group.
MATERIALS AND METHODS Design
To determine whether rimonabant decreases liver fat in proportion to changes in body weight we used two approaches. First, we recruited subjects for a 48-week weight loss study in which subjects used either rimonabant or placebo in a double-blind randomized manner. This design leads to a difference in body weight loss and allows weight-independent effects on liver fat content to be examined by statistical adjustment for a change in body weight. To compliment this analysis with another one, we also compared effects of rimonabant-induced changes in liver fat content to those induced by a hypocaloric diet alone in a young historical reference group. 12 The latter study was performed in our laboratory using the exact same methodology as in the rimonabant and placebo groups. Data from this study have been reported earlier. 12 
Subjects
Subjects were recruited based on a newspaper advertisement. The inclusion criteria for the rimonabant study were (i) age between 35 and 70 years, (ii) the presence of the metabolic syndrome as defined by the International Diabetes Federation criteria, 13 (iii) no acute or chronic disease other than obesity based on medical history, physical examination, standard laboratory tests (blood counts, serum (S) electrolytes and creatinine, fasting serum (fS) glucose, thyroid stimulating hormone, viral hepatitis serology) and electrocardiogram. Exclusion criteria included (i) pregnancy, (ii) type 1 or 2 diabetes, (iii) cannabis consumption (based on medical history and the tetrahydrocannabinoid test), (iv) weight loss exceeding 5 kg during 3 months before the study and (v) history of bariatric surgery. The study protocol was approved by the Medical Ethics Committee of the Helsinki University Central Hospital, and each subject provided their written informed consent. The study was registered in the Finnish National Clinical Trial Register at http://www.hus.fi with the identification number 215409.
In the historical hypocaloric diet group, inclusion criteria included a history of gestational diabetes, age between 20 and 50 years and postpartum body mass index (BMI) between 28 and 35 kg m À 2 , exclusion criteria included type 2 diabetes and other acute or chronic diseases. 12 Metabolic study Eligible patients were randomized in a double-blind manner to receive either rimonabant (20 mg) or an identical-looking placebo for 48 weeks. Before initiation and after completion of the treatment course, they participated in a metabolic study that consisted of three visits within 3 days. On one occasion, blood samples were drawn after an overnight fast for measurement of complete blood count, electrolytes and creatinine, lipids, liver enzymes and glycosylated hemoglobin A 1c . Blood pressure was measured in the sitting position after 10-15 min of acclimatization using a random-zero sphygmomanometer (Erka, Chemnitz, Germany). On the other two visits, abdominal subcutaneous and intra-abdominal fat volumes were measured using magnetic resonance imaging, and liver fat content using 1 H-MRS as detailed below. During the study, the patients received dietary and lifestyle advice at baseline, after 1 month and thereafter every second month until the final visit of the study. No other anti-obesity agents were used.
Liver fat content
Liver fat content was measured in the rimonabant and placebo as well as in the historical hypocaloric diet group 12 using 1 H-MRS as previously described in detail.
14 Subjects were allowed to breathe freely during data collection. All spectra were analyzed with an analysis program VAPRO-MRUI (http://www.mrui.uab.es/mrui/).
Body composition
Body weight and height were measured bare foot in light clothing to calculate BMI (weight, kg/(height, m) 2 ). Waist circumference was measured midway between the spina iliaca superior and the lower rib margin. Abdominal subcutaneous and intra-abdominal fat volumes were quantified by analyzing 16 T1-weighted two-dimensional fast low angle shot trans-axial magnetic resonance imaging scans reaching 8 cm above and 8 cm below the 4th and 5th lumbar interspace using a Magnetom Vision scanner as described previously.
14 The magnetic resonance images were analyzed by a segmentation software SliceOmatic v4.3 (Tomovision, Montreal, Canada). The areas of subcutaneous and intra-abdominal fat were measured for each slice using a region-growing routine. The results were expressed as total volumes of intra-abdominal fat tissues. The same magnetic resonance imaging methodology was used in the hypocaloric diet group. 12 Analytical procedures Plasma (P) glucose, glycosylated hemoglobin A 1c , S-insulin, S-highdensity lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol, S-triglyceride and S-alanine aminotransferase (S-ALT), aspartate aminotransferase (S-AST) and gamma-glutamyl transferase (S-gGT) concentrations were measured as described previously. 12 Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated by multiplying fasting insulin (mU l À 1 ) by fasting glucose (mmol l À 1 ) divided by 22.5.
15 P-sodium and potassium concentrations were determined with indirect ion-selective electrodes and p-creatinine with an enzymatic kit from Roche Diagnostics using an autoanalyzer (Roche Diagnostics Hitachi Modulator, Hitachi Ltd, Tokyo, Japan). Blood count were performed using a flow cytometric method on a Sysmex apparatus (TOA Medical Electronics Co. Ltd, Kobe, Japan).
Statistical analyses All data were tested for normality of distribution using a KolmogorovSmirnov test. Normally distributed data are given as means±s.e.m. and non-normally distributed data are shown as median (25-75% percentile). Unpaired t-test and Mann-Whitney test were used to compare the differences between baseline parameters and changes between the study groups for normally and non-normally distributed data, respectively. Categorical variables were compared using Fisher's exact test. Spearman's rank correlation coefficients were calculated to determine associations between liver fat, body weight and intra-abdominal fat. Analysis of covariance was used to compare differences between the three study groups and to adjust for change in body weight or BMI. Analysis of covariance was also used to compare slopes and intercepts of regression lines for the study groups. The study had 80% power to exclude a 30% weight-independent effect of rimonabant on liver fat based on data on weight loss-induced changes in liver fat measured by 1 H-MRS at an a-error level of 0.05. 16, 17 Calculations were made using the GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA) and SPSS 17.0 for Windows (SPSS, Chicago, IL, USA). A P-value of o0.05 was considered statistically significant.
RESULTS

Baseline characteristics
The rimonabant and the placebo groups were comparable with respect to age, gender, body weight and composition, fasting lipids, glucose and insulin concentrations, liver enzymes and liver fat content ( Table 1 ). The historical hypocaloric diet was comparable with the rimonabant and the placebo groups with respect to all of the aforementioned parameters except for age, being younger than the presently investigated subjects. 12 Body weight Absolute weight loss averaged 8.5±1.4 kg in the rimonabant, 1.7±1.0 kg in the placebo, and 7.5±0.2 kg in the historical hypocaloric diet group 12 ( Figure 1a) . The percentage weight losses averaged 8.5 ± 1.3%, 2.1 ± 1.2% and 8.3 ± 0.1%, 12 respectively.
Liver fat Liver fat decreased more in the rimonabant than in the placebo group (Po0.05 for difference between the groups). The percentage change in body weight correlated closely with the percentage loss of liver fat (r ¼ 0.70, Po0.0001; Figure 2a ). Neither the slopes nor the intercepts of these relationships differed significantly between the rimonabant and the placebo groups (Figure 2a ). When the change in liver fat in the rimonabant and placebo groups was adjusted for changes in body weight or BMI, the decrease in liver fat was not significant (P ¼ 0.57 after adjusting for changes in body weight; P ¼ 0.90 after adjusting for changes in BMI). The decreases in liver fat were comparable in the rimonabant and the young historical hypocaloric diet group 12 ( Figure 1b) .
Intra-abdominal fat
The percentage decrease in intra-abdominal fat was positively correlated with the percentage decrease in liver fat (Figure 2b) . The relationship was similar in both the rimonabant and the placebo groups. The mean decrease in intra-abdominal fat in the rimonabant group was 28±5%, which was significantly greater than in the placebo group (7 ± 2%, P ¼ 0.001). From the regression line relating the percentage change in intra-abdominal fat to that in liver fat in the rimonabant and the placebo groups, it could be calculated that a 16% (that is, the mean percentage decrease in intra-abdominal fat in the young hypocaloric diet group) decrease in intra-abdominal fat corresponded to B33% decrease in liver fat (Figure 2b ). This decrease was comparable to that seen in the historical hypocaloric diet group 12 (Figures 1d and 2b ).
Metabolic parameters S-ALT decreased significantly in the rimonabant group as it had in the young historical hypocaloric diet group, 12 but remained unchanged in the placebo group (Table 1) . S-gGT decreased significantly in the rimonabant group (Table 1) . In comparison, the decrease was borderline significant in the historical hypocaloric diet group (P ¼ 0.07), 12 and non-significant in the placebo group (Table 1) . There were no statistically significant changes in S-AST concentrations in any of the groups (Table 1) . fS-triglycerides decreased significantly in the rimonabant group, whereas the decrease did not reach significance in the placebo group (Table 1 ) or in the young historical hypocaloric diet (P ¼ 0.14) group. 12 fS-HDL cholesterol increased significantly in the rimonabant group, but remained unchanged in the placebo group (Table 1) as it had in the historical hypocaloric diet group (P ¼ 0.76).
12 fS-LDL cholesterol did not change in the rimonabant or the placebo groups (Table 1) , but had decreased significantly from 3.3 ± 0.1 to 2.9 ± 0.1 mmol l À 1 in the young historical hypocaloric diet group (Po0.001). Of note, the rimonabant and the young hypocaloric diet groups were comparable with respect to the tested parameters. 12 Data are given as mean±s.e.m. *Po0.05, **Po0.05 and ***Po0.0005. Comparison between before vs after the placebo treatment.
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Fasting plasma (fP) glucose decreased significantly in the rimonabant group (Table 1) . The decrease in fP-glucose was not statistically significant in the placebo group (Table 1 ) or in the young historical hypocaloric diet group (P ¼ 0.12).
12 fS-insulin decreased significantly in the rimonabant group as it had decreased in the historical hypocaloric diet group (P ¼ 0.04), 12 but remained unchanged in the placebo group (Table 1) . HOMA-IR decreased significantly in the rimonabant group (Table 1) , as it had in the young historical hypocaloric diet group (Po0.0005), 12 but remained unchanged in the placebo group (Table 1) .
DISCUSSION
In this investigator-initiated study, we set out to quantitate the effects of CB 1 blockade with rimonabant on liver fat content in humans. To this end, we performed a double-blind placebocontrolled study in which liver fat was measured using a state-ofthe-art method, 1 H-MRS 18 in all study groups. Weight loss over 48 weeks averaged 8.5% in the rimonabant group, which is comparable to that in the RIO [8] [9] [10] and the ADAGIO 11 studies. Liver fat decreased significantly more in the rimonabant than in the placebo group. This between-group difference disappeared after adjusting for weight loss. The loss of liver fat was also compared retrospectively to that of a young historical group placed on a hypocaloric diet, 12 which induced similar weight loss as was observed in the rimonabant group (Figure 1a) . In the historical hypocaloric diet group, also liver fat decreased similarly to that in the rimonabant group (Figure 1b) . Regarding the latter comparison, however, it must be beared in mind that the subjects were recruited to the rimonabant and the historical hypocaloric diet study groups on a different basis. The inclusion criteria were the presence of the metabolic syndrome and prior history of gestational diabetes, respectively. Furthermore, this study included 70% women with a median age of 58 years, whereas the historical hypocaloric diet group consisted of women only with a median age of 37 years. These differences could potentially compromise the comparability of the two data sets.
Data from animal and a few human studies suggest that endocannabinoids may be involved in the pathogenesis of hepatic steatosis. In obese Zucker rats, high-dose (30 mg kg À 1 ) rimonabant treatment has been shown to reduce liver enzyme concentrations and hepatic steatosis. 19 The changes in liver enzymes and liver fat were not related to changes in body weight. In mice fed a high-fat diet, liver-specific knockout of CB 1 receptors alleviated hepatic steatosis, although the knockout animals developed a similar degree of obesity as did their wild-type littermates. 7 In humans, daily cannabis use is associated with an increased risk of hepatic fat accumulation in subjects with chronic hepatitis C. 20 In obese subjects, serum endocannabinoid concentrations have been reported to be increased. 21, 22 A recent hepatic venous catheterization study in obese subjects with NAFLD also showed that the splanchnic region takes up the endocannabinoid 2-arachidonoylglycerol. 23 Moreover, both arterial and hepatic venous concentrations of 2-arachidonoylglycerol were positively related to liver fat content. 23 These studies do not, however, establish causality between endocannabinoids and hepatic steatosis.
The effect of rimonabant on liver enzymes has previously been reported in two double-blind placebo-controlled trials. 8, 11 In these studies, rimonabant decreased concentrations of S-ALT, S-AST and S-gGT significantly. In addition, a significantly greater increase in the liver-to-spleen attenuation ratio, a qualitative measure of liver fat content, was found in subjects on the rimonabant vs those on the placebo treatment. 11 There are, however, no data quantitating effects of rimonabant on liver fat in humans. In overweight or obese non-diabetic subjects, loss of 3%, 24 16 respectively. These decreases in liver fat are comparable to those seen in the rimonabant group in this study.
This study was initiated before rimonabant was withdrawn from the market because of psychiatric side effects. 26 We tested the exciting possibility that rimonabant might be helpful in the treatment of NAFLD irrespective of changes in body weight. The key finding was that of a close positive correlation between changes in body weight and liver fat content during 48 week of weight loss treatment. The study was powered to exclude a 430% weight-independent effect of rimonabant on liver fat. Thus, a weight-independent effect of rimonabant of o30% could exist. However, the present data show that the major factor regulating changes in liver fat content in humans during rimonabant treatment is the change in body weight. These data differ from those in mice in whom effects of rimonabant on liver enzymes and liver fat content could not be attributed to changes in body weight, and argue against a significant role of CB 1 -mediated involvement of the endocannabinoid system in the pathogenesis of NAFLD in humans. Even so, the data emphasize the need to develop pharmacological and non-pharmacological approaches to fight obesity. A CB 1 blocker without the side effects of rimonabant would be helpful in this respect. (--) indicate mean decrease in the rimonabant and the placebo groups, and dashed lines ( À À À ) indicate mean decrease in the hypocaloric diet group. From the regression line relating the percentage change in body weight to that in liver fat in the rimonabant and the placebo groups, it can be calculated that a 8.3% decrease in body weight (that is, the mean percentage weight loss in the young hypocaloric diet group 12 ) corresponds to decrease in liver fat similar to that seen in the rimonabant and placebo groups upon similar weight loss.
